4.7 Article

Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation Study

Journal

JOURNAL OF PERSONALIZED MEDICINE
Volume 11, Issue 11, Pages -

Publisher

MDPI
DOI: 10.3390/jpm11111233

Keywords

pharmacogenomics; cisplatin; nephrotoxicity; kidney injury; genetic polymorphisms; genome-wide association study; platinum

Funding

  1. US NCI
  2. Indonesia Endowment Fund for Education (LPDP) Ministry of Finance, the Republic of Indonesia [20161022049506]
  3. Princess Margaret Cancer Foundation (LusiWong Family Fund)
  4. Princess Margaret Cancer Foundation (Alan Brown Chair in Molecular Genomics)
  5. Princess Margaret Cancer Foundation (Wharton family)
  6. Princess Margaret Cancer Foundation (Joe's Team)
  7. Princess Margaret Cancer Foundation (Gordon Tozer, Bruce Galloway and the Elia family)
  8. Princess Margaret Cancer Foundation (Princess Margaret Hospital Head and Neck Cancer Translational Research Program)
  9. St Antonius Onderzoeksfonds
  10. Roche Nederland B.V.

Ask authors/readers for more resources

This study identified a specific variant of the BACH2 gene that may play an important role in cisplatin-induced nephrotoxicity, suggesting opportunities for mechanistic research, tailored therapy, and preventive strategies related to this pathology.
This study aims to evaluate genetic risk factors for cisplatin-induced nephrotoxicity by investigating not previously studied genetic risk variants and further examining previously reported genetic associations. A genome-wide study (GWAS) was conducted in genetically estimated Europeans in a discovery cohort of cisplatin-treated adults from Toronto, Canada, followed by a candidate gene approach in a validation cohort from the Netherlands. In addition, previously reported genetic associations were further examined in both the discovery and validation cohorts. The outcome, nephrotoxicity, was assessed in two ways: (i) decreased estimated glomerular filtration rate (eGFR), calculated using the Chronic Kidney Disease Epidemiology Collaboration formula (CKD-EPI) and (ii) increased serum creatinine according to the Common Terminology Criteria for Adverse Events v4.03 for acute kidney injury (AKI-CTCAE). Four different Illumina arrays were used for genotyping. Standard quality control was applied for pre- and post-genotype imputation data. In the discovery cohort (n = 608), five single-nucleotide polymorphisms (SNPs) reached genome-wide significance. The A allele in rs4388268 (minor allele frequency = 0.23), an intronic variant of the BACH2 gene, was consistently associated with increased risk of cisplatin-induced nephrotoxicity in both definitions, meeting genome-wide significance (beta = -8.4, 95% CI -11.4--5.4, p = 3.9 x 10(-8)) for decreased eGFR and reaching suggestive association (OR = 3.9, 95% CI 2.3-6.7, p = 7.4 x 10(-7)) by AKI-CTCAE. In the validation cohort of 149 patients, this variant was identified with the same direction of effect (eGFR: beta = -1.5, 95% CI -5.3-2.4, AKI-CTCAE: OR = 1.7, 95% CI 0.8-3.5). Findings of our previously published candidate gene study could not be confirmed after correction for multiple testing. Genetic predisposition of BACH2 (rs4388268) might be important in the development of cisplatin-induced nephrotoxicity, indicating opportunities for mechanistic understanding, tailored therapy and preventive strategies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available